BioMarin Pharmaceuticals reported strong revenue growth, successful acquisition of Inozyme, and significant progress in their pipeline, which were slightly offset by increased operating expenses and adjusted revenue guidance for VOXZOGO.

Company Guidance -

Q3 2025

During BioMarin Pharmaceuticals' second-quarter 2025 call, the company provided updated guidance reflecting robust financial and operational performance. The guidance highlighted an increase in full-year 2025 total revenue expectations, now projected between $3.125 billion, supported by 16% revenue growth in Q2. Key drivers included a 20% year-over-year surge in VOXZOGO revenue, totaling $221 million, and a 15% increase in enzyme therapies revenue, reaching $555 million. The company also raised its non-GAAP operating margin guidance to between 33% and 34%, and non-GAAP earnings per share are now anticipated to range from $4.40 to $4.55. This upward revision is attributed to strong commercial execution, particularly VOXZOGO's global expansion and strategic initiatives within its Skeletal Conditions business unit. Additionally, BioMarin reiterated its commitment to advancing its pipeline, including BMN 333 and BMN 401, while emphasizing continued strategic business development to enhance its growth strategy.

Strong Revenue Growth

Total revenues grew 16% in Q2 2025 and 15% in the first half of 2025 compared to the same period in 2024, driven by global demand and new patient starts.

VOXZOGO Revenue Increase

VOXZOGO revenue increased 20% year-over-year to $221 million, with expectations for second half revenue to be higher than the first half.

Inozyme Acquisition

Successfully completed the acquisition of Inozyme on July 1, broadening the enzyme therapies portfolio with BMN 401.

Pipeline Progress

BMN 333 achieved target profile for achondroplasia, with plans to advance to a Phase II/III study. BMN 401 pivotal data expected in 2026.

Profitability Expansion

Non-GAAP diluted earnings per share increased more than 3x the rate of revenue growth, reflecting strong operating margin performance.

BioMarin Pharmaceutical (BMRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BMRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	0.87 / -	0.55	―	―	―
Aug 04, 2025	2025 (Q2)	0.86 / 1.23	0.55	123.64% (+0.68)
May 01, 2025	2025 (Q1)	0.71 / 0.95	0.46	106.52% (+0.49)
Feb 19, 2025	2024 (Q4)	0.53 / 0.64	0.11	481.82% (+0.53)
Oct 29, 2024	2024 (Q3)	0.53 / 0.55	0.21	161.90% (+0.34)
Aug 05, 2024	2024 (Q2)	0.36 / 0.55	0.29	89.66% (+0.26)
Apr 24, 2024	2024 (Q1)	0.31 / 0.46	0.27	70.37% (+0.19)
Feb 22, 2024	2023 (Q4)	0.20 / 0.11	0	―
Nov 01, 2023	2023 (Q3)	0.22 / 0.21	-0.04	625.00% (+0.25)
Jul 31, 2023	2023 (Q2)	0.21 / 0.29	0.15	93.33% (+0.14)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BMRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$60.31	$61.93	+2.69%
May 01, 2025	$62.71	$62.03	-1.08%
Feb 19, 2025	$65.61	$68.73	+4.76%
Oct 29, 2024	$69.91	$66.68	-4.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.